Iterative Health White Logo

Iterative Health

Our Exclusive Partner for Artificial Intelligence

Artificial intelligence (AI) is fueling the future of healthcare technology and Provation’s solutions. Together, Provation and Iterative Health are empowering clinicians, life science researchers, and other healthcare leaders with the tools needed to work smarter, faster, and with more accuracy. After all, the quality of patient care depends on it.​

We’re on a mission to minimize disparities in healthcare with the help of scalable AI technology from Iterative Health

Provation is proud to partner with Iterative Health, pioneers in the application of artificial intelligence-based precision medicine to gastroenterology. Together we’re driven to establish a new standard of care for the detection, and ultimately, treatment of gastrointestinal (GI) diseases. Our collective goal is to improve the speed, accuracy, and consistency of endoscopy readings, clinical trial recruitment, and procedure documentation – and we are doing so by integrating powerful, proprietary AI and computer vision technologies into our key solutions, like Provation® Apex.​

Iterative Scopes - Artificial Intelligence

Optimized patient recruitment ​ for IBD clinical trials – made possible with artificial intelligence

Whether you are running IBD clinical trials today, or new to clinical trials altogether, we can help relieve much of the patient recruitment burden for you.

AI Technology for Gastroenterology and Endoscopy​ ​

AI-Assisted Polyp Detection: SKOUT™​

White SKOUT Logo
Image detected by SKOUT
Detection of a 4-mm adenoma in the hepatic flexure by the SKOUT CADe device

Detect more adenomas during colonoscopy with SKOUT™ CADe​

SKOUT, a computer-aided detection (CADe) device from our AI partners Iterative Health, uses advanced computer-vision technology to recognize potentially suspicious colorectal polyps and provides gastroenterologists with real-time feedback, with the goal of early lesion detection.

A recent study has shown SKOUT to increase overall adenoma detection by up to 27%.1 SKOUT does not replace a full patient examination or physician judgement, however, it can assist endoscopists by analyzing colonoscopy video feed in real time to identify polyps and present visual indicators.


SKOUT has achieved FDA 510(k) clearance and is coming soon (not yet available for sale in the United States).

Sign up today to be alerted when SKOUT is available.​

1Shaukat A, Lichtenstein D, Somers S, et al. (2022). Computer-Aided Detection Improves Adenomas per Colonoscopy for Screening and Surveillance Colonoscopy: A Randomized Trial. Gastroenterology.

AI Patient Recruitment

AI Patient Recruitment

Help accelerate the development of new therapies for your inflammatory bowel disease (IBD) patients with AI patient recruitment. This new service is designed to help clinicians, healthcare organizations, and pharmaceutical companies more efficiently and accurately identify prospective clinical trial candidates for IBD trials.​


AI Procedure Documentation

Provation is always seeking to further minimize the burden of physician documentation for endoscopic procedures. That’s why we’ve partnered with Iterative Scopes to develop an AI documentation integration that will enable direct scope to text interpretation – coming soon to Provation® Apex.

Latest News & Studies

Sept. 22, 2022

Iterative Health Receives FDA Clearance for AI-Assisted Polyp Detection Device SKOUT™

April 14, 2022

Enhancing the Standard of Care in Gastroenterology: Artificial Intelligence Applications

Feb. 22, 2022

Can an AI-driven data sharing effort advance IBD treatments? (Drug Discovery World)

Connecting you with the top talent in healthcare and AI ​

solve the puzzle

Massachusetts-based Iterative Health, formerly known as Iterative Scopes, spun out of MIT in 2017 by founder and CEO, Jonathan Ng, MBBS. Now, Iterative Health is making waves throughout gastroenterology with significant achievements, including:

  • A network of partnerships with leading cross-industry GI stakeholders​
  • Top talent on its leadership team and scientific and industry advisory boards​
  • The backing of top tier financial institutions​
  • $150 million Series B financing round in December 2021​
  • $195 million + in investor funding since 2021​

​And we’re just getting started.​

Scroll to Top